Background: Tumor resistance to chemotherapy may be present at the beginning of treatment, develop during treatment, or become apparent on re-treatment of the patient. The mechanisms involved are usually inferred from experiments with cell lines, as studies in tumor-derived cells are difficult. Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal selection leads to the resistance of recurrent tumors.
Background
Tumor resistance to chemotherapy is a well-known clinical phenomenon that is now yielding its secrets to investigation at the molecular level in biopsy material. Studies in cell lines do not always correlate well with results from tumor tissue [1] , which may consist largely of non-neoplastic cells that support and modify the biology of neoplastic cells. Thus it is important to validate the mechanisms important in vitro with the situation in the patient. Nevertheless, cell line studies and immunohistochemical studies of tumors suggest that resistance is a selective process: only those cells that survive a druginduced insult will re-grow.
We have previously shown development of such resistance to combination chemotherapy in tumor-derived cells from matched biopsies collected from breast cancer patients before and after administration of doxorubicincontaining chemotherapy [2] . In this study we show similar results in patients with esophageal cancer from biopsies obtained prior to and several months after chemotherapy. Two cycles of the combination of epirubicin, cisplatin and 5-FU (ECF) are given to these patients prior to resection, allowing studies to be performed with paired samples before and after chemotherapy. We have used real-time quantitative RT-PCR (qRT-PCR) and immunohistochemistry (IHC) to assess targets known to be of importance to resistance to these agents.
The mechanisms involved in resistance to chemotherapy usually involve up-regulation of resistance mechanisms, or down-regulation of target genes. Examples of the former include drug efflux pump molecules such as multidrug resistance gene 1/P-glycoprotein (MDR1/P-gp), while the latter include topoisomerases (TOPOs), targets of drugs such as etoposide and doxorubicin. Many papers attest to the importance of clonal selection in this process: it is for instance possible to expose cell lines to low concentrations of drugs and, over time, to produce highly resistant sub-clones [3] . However, there is another potential mechanism that does not require clonal selection: cells may be able to adapt by regulation of expression of resistance or target molecules individually if they survive the initial exposure to the drug. This could be a more rapid process and would require changes in molecular expression, possibly due to epigenetic change, rather than genetic mechanisms such as mutation [4] . As a result, resistance may therefore arise rapidly following treatment with chemotherapy.
Recent studies have shown that the expression of MDR1/ P-gp is up-regulated within hours of anti-cancer drug treatment in vivo in patient samples [5] [6] [7] [8] , although this effect was not observed in all patients. We therefore wished to examine how quickly and in how many cases these resistance molecules were up-regulated in tumorderived cells from several tumor types. We have used selective short-term cell culture (6 days) to examine the changes in expression that occur following exposure to chemotherapy compared to medium-only control cells from the same samples. Our short-term culture system employs a serum-free medium and polypropylene 96 'U' well microplates. This inhibits the proliferation and survival of normal cells and allows selective survival of a neoplastic cell population [9] . The short incubation period also limits the possibility of selection of clones or subpopulations in vitro. However, the presence of non-neoplastic cells for most of the incubation period allows the interaction between stromal cells and neoplastic cells, a factor that appears to be important to maintain the chemosensitivity profile [10] .
Methods

Patients and tissue samples for in vitro studies
Tumor derived cells were obtained from 17 breast cancer patients (16 primaries; 1 pre-treated with mitoxantrone and paclitaxel), 13 ovarian cancer patients (all pre-treated with a cisplatin-based regimen), 10 colorectal cancer patients (all primaries) and 7 esophageal cancer patients (3 untreated; 4 treated with ECF). Cells were grown for 6 days in serum-free medium with or without drugs, before RNA extraction and further PCR analysis.
Patients and tissue samples for in vivo study
Thirty-four esophageal adenocarcinoma biopsies, thirtytwo of which were paired samples were obtained from patients (17M:1F; median age 57, range 42-81) before and after administration of 2 cycles of ECF chemotherapy. After enzymatic digestion, tumor derived cells were centrifuged over Ficoll (Sigma Chemical Co, Poole, UK, Cat. No. 1077-1) to remove blood contaminating cells, washed in PBS, and stored in RNA later (Ambion, Huntingdon, UK) at -80°C until further molecular analysis was performed. Tissue sections from these samples were stained for GST-π, MRP1, P-gp and TS. All tumor samples were removed as part of patient treatment, with consent for tissue donation and local research ethics committee approval for use of the tissue surplus to diagnostic requirements for cellular and molecular assays. Chemosensitivity data were available for 9 patients with recurrent ovarian cancer, before treatment and on relapse, though in only one case was material available from both samples for quantitative RT-PCR.
Drugs
Cisplatin, 5-fluorouracil (5-FU), epirubicin, doxorubicin, irinotecan, paclitaxel (Taxol ® ) and topotecan (Hycamptin ® ) were obtained from the pharmacy at Queen Alexandra Hospital (Portsmouth, UK). Cisplatin, 5-FU, irinotecan and paclitaxel were stored at room temperature, while all other drugs were stored at -20°C, as previously reported [11] . Test drug concentrations (TDC) were 10.0 µM for cisplatin, 345 µM for 5-FU, 148 µM for irinotecan, 15.9 µM for paclitaxel, 2.5 µM for doxorubicin, 0.862 µM for epirubicin, and 1.64 µM for topotecan. Combinations were made up by adding two or three drugs concurrently at their 200% TDC at the beginning of the ATP-cell viability assay and diluted in a constant ratio: sequential studies were not performed.
Short-term cell culture
Briefly, tumor tissue or fluid was taken by a histopathologist or surgeon under sterile conditions, and transported to the laboratory in cell culture medium of Dulbecco's modified Eagle's medium (DMEM; Sigma Cat No. D5671) with antibiotics (100 U/ml penicillin and 100 µg/ ml streptomycin, Sigma, Cat No. P0781) at 4°C. Cells were obtained from solid tumors by enzymatic dissociation, usually 0.75 mg/ml collagenase (Sigma Cat No. C-8051) overnight. Viable tumor-derived cells were purified by density centrifugation (Histopaque 1077-1, Sigma), washed, counted and resuspended to 100,000 cells/ml in case of effusions or 200,000 cells/ml for solid biopsies. In the meantime 96-well polypropylene microplates (Corning-Costar, High Wycombe, UK; Cat No. 3790) were prepared with each drug/combination at six doubling dilutions in triplicate from 200% TDC to 6.25% TDC, according to Andreotti et al. [9] . Approximately 10,000-20,000 cells/well were added to the plates to a final volume of 200 µl/well. The plates were then incubated at 37°C in 5% CO 2 for 6 days, after which the degree of cell inhibition was assessed by measurement of the remaining ATP in comparison with negative control (no drug, MO) and positive control (maximum inhibitor, MI) rows of 12 wells each. Prior to cell lysis with an ATP-extracting reagent, an aliquot of 150 µl of cell suspension were removed from each well, centrifuged, washed with phosphate buffered saline (PBS) and stored at -80°C in a GTIC-containing solution (lysis buffer RA1, Macherey-Nagel, Düren, Germany; Cat. No.740961) until further molecular analysis was carried out. The RNA was subsequently extracted from aliquots that had been exposed to a drug concentration capable of inhibiting cell growth by 40-60%. ATP was extracted from the remaining 50 µl cell suspension and measured by light output in a microplate luminometer (Berthold Diagnostic Systems GmbH, Pforzheim, Germany) following addition of luciferin-luciferase.
RNA extraction
Cells obtained after enzymatic dissociation from endoscopic esophageal biopsies or short term cell culture were either resuspended in RNA later (Ambion, Huntingdon, UK; Cat No. 7020) or lysed with buffer RA1 and stored at -80°C until RNA extraction. Total RNA was extracted from at least 50,000 cells with a commercially available kit (NucleoSpin ® RNA II mini, Macherey-Nagel; Cat No. 740955) according to the manufacturer's instructions. The protocol included a DNase digestion step to prevent carry-over of genomic DNA in further analysis.
qRT-PCR
A two-step protocol was employed. Firstly, total RNA was reverse-transcribed using the Promega reverse transcription system (Promega, Southampton, UK; Cat No. (Table 1) , 200 µM each dATP, dCTP, dGTP, 400 µM dUTP, 3.0-5.0 mM MgCl 2 , 0.125 units AMPErase ® UNG, 0.625 units of Ampl-iTaq Gold DNA polymerase and 1 × SYBR Green PCR buffer (all reagents were from Applied Biosystems, Warrington, UK). Product amplification was performed up to 45 PCR cycles, after uracil removal (2 min at 50°C) and polymerase activation (10 min at 95°C). Each two-step PCR cycle comprised denaturing (15 s at 95°C), annealing, and extending (1 min at 60°C). At the end of each run a final melt curve cycle (cooling to 50°C and then increasing stepwise 1°C to 95°C) was performed to exclude the presence of primer-dimer artefacts. At least 3 housekeeping genes were used for each experiment chosen from the following: glyceraldehyde-3 phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1), human porphobilinogen deaminase (PBGD), succinate dehydrogenase complex-subunit A (SDHA) and TATA box binding protein (TBP). The internal reference genes were selected due to their relative low abundance in normal tissue [12] . The housekeeping genes were amplified parallel to the target genes in separate wells. When possible, primer sequences (Table 1) were chosen to span exon boundaries to the following targets: breast cancer resistance protein (BCRP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), excision repair cross-complementing 1 (ERCC1) gene, glutathione-S-transferase isoform π (GST-π), multi-drug resistance gene 1 (MDR1), MLH1, multi-drug resistance related protein 1 (MRP1), multi-drug resistance related protein 2 (MRP2), metallothionein (MT), major vault protein (MVP), thymidine phosphorylase (TP), thymidylate synthase (TS), topoisomerase I (TOPO I), topoisomerase IIα and β (TOPO IIα and TOPO IIβ). Each amplicon was amplified in a separate reaction to prevent competition among multiple sets of primers. A positive control (pooled c-DNA from a variety of human tumors, including breast, ovarian, colorectal and esophageal carcinoma) and negative controls with no template and RTnegative as template were added in every experiment. All assays were run in triplicate. Validation experiments were run to show that the efficiencies of the target and reference genes amplifications were approximately equal, and in the range 95-105%. The PCR cycle number that generated the first fluorescence signal above a threshold (threshold cycle, Ct; 10 standard deviations above the mean fluorescence generated during the baseline cycles) was determined, and a comparative Ct method was then used to measure relative gene expression [13] . The following formula was used to calculate the relative amount of the transcript in the sample: 2 -∆∆Ct , where ∆Ct is the difference in Ct between the gene of interest and the mean of the at least two reference genes, and ∆∆Ct = ∆Ct of drug nonexposed cells -∆Ct of drug-exposed cells, for the ex-vivo experiments, or ∆∆Ct = ∆Ct of pre-chemotherapy sample -∆Ct of post-chemotherapy sample, for matched tumor biopsies.
Immunohistochemistry
The monoclonal antibodies (Abs) for GST-π, MRP1, Pg-p, and TP ( 
Data analysis
The luminometer readings obtained from the ATP-TCA were entered into an Excel 2000 spreadsheet (Microsoft) which calculated the percentage of cell inhibition for each drug concentration according to the previous published formula: 1 -[(Test -MI)/(MO -MI)]*100 [9] . For each drug-response curve, the 50% inhibitory concentration (IC50) and the 90% inhibitory concentration (IC90) were also calculated as previously described [14] .
Assessment of slides was done using the H-score. Staining intensity (none, 0 points; weak, 1 point; moderate, 2 points; strong, 3 points) and percentage of positive tumor cells were multiplied to achieve a score between 0 and 300. A H-score of 100 or more was regarded as positive and results less than 100 were regarded as negative. The correlation coefficients were calculated by the method of the least squares, and the correlation between the IC90 and IC50 values and immunohistochemistry indices was assessed using univariate linear regression (Statsdirect, Sale, UK).
Non-parametric statistical methods were used. The calculated and descriptive data were entered into an Access 2000 database (Microsoft) and analysed using a Wilcoxon two-tailed paired rank sum test for paired data or the 
Results
Chemotherapy-induced changes in mRNA levels in biopsy material
Figures 1a-e illustrate changes to IC50 µM values in preand post chemotherapy ovarian tumor-derived cells tested with a variety of chemotherapeutic agents. There is a general increase in resistance to doxorubicin when anthracycline-based regimens (mitoxantrone + paclitaxel or liposomal doxorubicin) are administered to ovarian cancer patients ( Fig. 1a ). We observed little cross-resistance for mitoxantrone, topotecan, paclitaxel, and cisplatin following anthracycline-based chemotherapy ( Fig.  1b-e ), [15] , although some patients do show alteration of sensitivity to other agents. Similar changes can be seen in breast cancer biopsies before and after administration of a chemotherapy regimen [2] . The increase in resistance to doxorubicin shown in Figure 1a was accompanied by changes in drug resistance gene expression. Figure 1f highlights such up-regulation of MDR1 and breast cancer resistance protein (BCRP) observed in ovarian-tumor derived cells from a single patient.
Membrane proteins such as MDR1/P-gp, multi-drug resistance protein 1 (MRP1) and major vault protein (MVP) have been demonstrated to confer resistance to epirubicin by pumping the cytotoxic drug out of cells [16] . Paired esophageal samples were obtained from the same six patients both before and after chemotherapy; in all 6 biopsy pairs (Table 3) , there was an increase of the mRNA levels of MDR1 following ECF chemotherapy ( Fig. 2a) . In a larger series of 20 esophageal samples (including those that did not have a paired biopsy), divided in two groups according to the patients' exposure to treatment, there was a 5-fold increase in MDR1 expression in the post-chemotherapy group (median expression index 0.07 pre-and 0.37 post-chemotherapy, p < 0.0001, Mann-Whitney non-parametric unpaired U test). The paired samples from patients before and after ECF chemotherapy also showed a trend towards increased expression of MRP1 and MVP (Table 3) , with three tumors showing concomitant up-regulation of both genes. Furthermore, the increased expression of MRP1 paralleled that of glutathione-S-transferase isoform π (GST-π) in 2 of these 3 samples, consistent with the mechanism of detoxification of MRP1 that involves transport of glutathione-conjugated molecules [17] .
We then determined the relative mRNA levels of enzymes that have previously been correlated with 5-FU sensitivity: dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and thymidylate synthase (TS) [18] . No significant difference was found for these 3 genes when we compared their expression pre-and post-chemotherapy in unpaired samples (Table 3 ). However, we found a modest increase of TS expression in 5/6 paired samples (Fig. 2b) , 3 of which also showed a concomitant decrease in TP levels. One sample showed a paradoxical decrease in TS, indicating some heterogeneity. Although the sample size is small, the trend of increased TS levels in ECF exposed tumors is consistent with a number of previous reports that demonstrated an acute induction of TS expression in cell lines, animal models and human tumors following 5-FU treatment [18, 19] .
It should be noted that these qRT-PCR results were all obtained from samples that included normal cells present in the tumor as well as neoplastic cells, and could be affected by changes in normal cells as well as malignant cells.
Chemotherapy-induced changes in protein levels in biopsy material
IHC was performed on 16 paired esophageal biopsies: qRT-PCR data were obtained for four of these pairs. Overall, we were able to confirm an increased expression of the MDR-1 encoded protein, P-gp (Table 4 ), in 8/16 paired tumor samples obtained from patients who had been exposed to ECF chemotherapy. TS positivity (Table 4 ) was found in 10/16 samples obtained before treatment and 10/16 post-chemotherapy specimens; in this instance the modest induction of TS seen at the mRNA level did not reflect an increase in protein level (data not shown). We found GST-π (Table 4 ) positivity in 5/16 pre-chemotherapy biopsies. In the post-chemotherapy specimens we detected strong expression of GST-π in all but one of the samples. In one case that had been negative at diagnosis we measured a marginal increase of mRNA levels with qRT-PCR. A total of 13/16 pre-and 12/16 post-chemotherapy biopsies were found to be positive for MRP1 (Table 4 ). Overall, these data show little correlation between the mRNA and the degree of expression of protein levels determined by IHC. Confounding factors may be the presence of non-cancerous cells as mentioned above, but also the nature of IHC, which is at best a semiquantitative technique.
Changes in short-term cell culture
Of the 47 solid tumor samples studied in short-term cultures, 7 were esophago-gastric, 17 were breast carcinomas, 13 were ovarian carcinomas and 10 were colorectal tumors. A total of 93 experiments were performed, as in Changes due to chemotherapy in biopsies taken before and after chemotherapy 
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Cisplatin IC50 M e) most cases the same sample was treated with 2 or more drugs.
Doxorubicin effects in short-term cell culture
In the first instance, we decided to study the effects of anthracycline exposure for 6 days on tumour-derived cells. Our in vitro experiments showed a significant downregulation of TOPO IIα; its median levels decreased from 0.546 (range 0.005-1.782) to 0.017 (range 0.0004-0.595) units in a group of 14 breast samples (p < 0.0001, Wilcoxon matched pairs test) and from 1.491 (range 0.080-6.884) to 0.089 (range 0.003-3.605) units in the ovarian cancer subgroup (p < 0.0015, Wilcoxon matched pairs test). The down-regulation of TOPO IIα levels was greater than 2-fold in 13/14 breast samples and in 9/12 ovarian samples (Fig. 3a ). It has been suggested that cancer cells can concomitantly down-regulate TOPO IIα and up-regulate TOPO I in response to treatment with topoisomerase II inhibitors [20] . In our series we noted a general trend of diminished levels of TOPO I, particularly in the ovarian subgroup (Fig 3b) . It is possible that doxorubicin exposure resulted in quiescence of cells which were not killed, and which would not therefore require higher levels of TOPO I, or that doxorubicin may also partly inhibit TOPO I, as suggested by a previous study [21] .
We observed a significant up-regulation of MRP-1 (p < 0.0001, Wilcoxon matched pairs test; Fig. 3c ) and of MVP (p < 0.0023, Wilcoxon; Table 5 ) in the breast cancer subgroup. The same effect was not found in the ovarian cancer group, in which the levels of MRP-1 and MVP increased over 0.5 fold in only 4/12 and 3/12 samples, respectively ( Table 5 ). No significant changes were found in the expression of MDR-1 and BCRP, although it should be noted that there was substantial heterogeneity among individual tumors (Table 5 ). For example, we measured a greater than 2-fold increase of MDR-1 levels in 2/12 ovarian samples (none of whom had received a MDR-1 pumped chemotherapeutic agent before), and a significant up-regulation of BCRP in 3/12 ovarian samples.
Topoisomerase I inhibitors effects in short-term cell culture
Subsequently we looked at the effect of 2-camptothecin derivatives, irinotecan and topotecan, on colorectal and ovarian tumor cells, respectively ( Table 6 ). As both compounds act by TOPO I inhibition, we firstly measured the levels of their target enzyme. We noted a trend towards down-regulation of TOPO I in treated cells: exposure to irinotecan decreased TOPO I levels >2-fold in 3/7 colorectal tumors, while topotecan caused down-regulation in 4/ 10 ovarian samples (Fig. 3d ). The decrease of TOPO I was accompanied by a concomitant reduction of TOPO IIα expression, which was particularly pronounced (>4-fold) in 6/7 colorectal tumors and 8/10 ovarian tumors (Fig.  3e ).
No significant changes were observed in the expression of the drug efflux molecules, MDR-1, BCRP and MRP-1 (Table 6) , though, as in the case of doxorubicin, considerable heterogeneity was noted. We observed an increase of BCRP levels after irinotecan or topotecan exposure in 2/7 colorectal samples and 3/9 ovarian samples.
Amongst the genes implicated in DNA repair (Table 6) , the modest down-regulation of MLH1 by topotecan exposure was not found statistically significant, although it was noted in 7/10 ovarian samples. Up-regulation of ERCC1 expression was found in all 10 ovarian cancer samples exposed to topotecan (p < 0.002, Wilcoxon), and in all 7 colorectal specimens treated with irinotecan, although in this group the increase was modest (p = 0.016, Wilcoxon). Changes in relative gene expression in 6 paired esophageal tumor biopsies -------------------------------------- 
3: Relative expression of mRNA levels in esophageal samples obtained from patients before and after chemotherapy (median values). The last 2 columns on the right represent values for the 12 paired biopsies. The p values have been calculated using non parametric statistics, and in detail the Mann Whitney U test for unpaired samples, and the
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Finally, we looked at EGFR as a marker of tumor growth and progression. After topotecan exposure we found a decrease (more than 2-fold) in the expression of this growth factor in 9/10 ovarian samples (Table 6) , with the median levels decreasing from 0.470 to 0.163 units (p < 0.0039, Wilcoxon).
5-FU effects in short-term cell culture
Preliminary data obtained from 2 esophageal biopsies indicated an increase of TS levels following 5-FU treatment. Subsequent in vitro experiments performed on material derived from 10 colorectal tumor samples and 13 breast tumor samples confirmed the expected increase of TS levels (Table 7) in the samples exposed to 5-FU (p < 0.0001, Wilcoxon; Fig. 3f ). The results indicated a general trend towards DPD down-regulation in the cells that had been exposed to 5-FU in vitro, though this effect was modest in most cases and we observed a greater than 2fold decrease in only 7/13 breast samples and 2/10 colorectal samples.
Cisplatin effects in short-term cell culture
We examined the mRNA expression levels of genes previously highlighted as important in cisplatin resistance in tumor-derived cells from 13 breast and 7 ovarian tumors ( Table 8 ). Up-regulation of the nucleoside excision repair (NER) gene ERCC1 has previously been shown to increase the removal of platinum affected DNA [22] . We observed a significant increase in ERCC1 levels in both tumorderived breast (p = 0.0266, Wilcoxon matched pairs test) and ovarian cells (p = 0.0156, Wilcoxon matched pairs test) (Fig 3g) . We also observed significant down regulation of a second DNA repair gene, MSH2 in tumor-derived breast cells (p = 0.0479, Wilcoxon matched pairs test), but not in tumor-derived ovarian cells. Samimi et al., [23] have previously demonstrated that following cisplatin therapy, there is selection for cells expressing lower hMLH1 and hMSH2. However, no significant changes were observed in the other mismatch repair genes, MLH1 and MSH6 in either tumor type (Table 8 ).
There was no significant change in MGMT in tumorderived breast or ovarian cells. However, it has previously been shown that MGMT mRNA levels begin to recover after 24 hours in the absence of drug [24] . There was a paradoxical decrease in the copper export pump ATP7B following cisplatin exposure (Table 8 ), in tumor-derived breast cells (p = 0.0327, Wilcoxon matched pairs test), but not in ovarian cells. No significant changes were observed in the heavy-metal binding protein MTII, in either tumor type.
ECF effects in short-term cell culture
We were able to study tumor-derived cells from 7 esophageal cancer patients, 4 of which had already been given ECF in vivo. The results mirror those obtained from paired esophageal biopsies: we noticed increased expression of TS in the cells that had been exposed to ECF (Fig 3h) . However, the expected up-regulation of MDR1 was only detected in 4/7 samples (data not shown), and may therefore be occurring in non-neoplastic cells that do not normally express MDR1, rather than in the neoplastic cells, which we found to express this molecule to the same degree pre-and post-treatment.
Correlation of in vitro cytotoxicity with molecular expression
Lastly, for 5-FU, doxorubicin and irinotecan, IC90 and IC50 data were obtained by measuring the ATP levels in a small aliquot of cell suspension at the end of the incubation period. This allowed a comparison to be made between drug sensitivity and the expression of putative resistance genes in the cells that had been exposed to chemotherapeutic agents. Using multivariate analysis, the IC90 of 5-FU was correlated with the median change of mRNA levels of both TS and DPD measured in 5-FU treated tumor-derived cells compared to control cells (expressed as 2 -∆∆Ct ) (R 2 = 0.872704; p = 0.0006 for DPD; p < 0.0001 for TS). In addition, expression of ERCC1 mRNA correlated with the IC50 values determined for doxorubicin in 11 breast samples (R = 0.7204, p < 0.0124). No other correlations were noted between sensitivity to the drugs and gene expression levels.
Discussion
Our results suggest that rapid adaptation to chemotherapy may result in a resistant phenotype. This is mediated by down-or up-regulation of genes that are usually correlated to the mechanism of action of the individual chemotherapeutic agent or relevant resistance mechanisms. Our data suggest that short-term cell culture of tumorderived cells with drugs could provide a suitable model for studying resistance mechanisms. The mechanisms observed appeared to be more specific to the drug used than to the tumor type: constitutive resistance probably reflects pre-chemotherapy expression of resistance mechanisms (e.g. drug efflux molecule expression in esophageal carcinoma). Acquired resistance develops rapidly and is likely to reflect changes in gene regulation rather than mutation-dependent selection of clones. Clonal selection may be important in some rapidly growing tumors and cell lines grown in serum-containing media, but is unlikely to be the major factor in solid tumors which have relatively low doubling rates. While mutation-mediated resistance can be much more profound than that observed here, our data suggest that the functional effects may still be sufficient to render the patient's tumor resistant to treatment within one cycle of chemotherapy.
Changes in resistance and target molecules
A large proportion of the published studies on resistance to chemotherapy have investigated the development of resistance using cell lines generated in the lab after prolonged and step-wise exposure to anti-cancer drugs. These in vitro models are not necessarily representative of the in vivo situation, when patients are usually administered one cycle of chemotherapy every 3-4 weeks. There are few studies in clinical samples. Our approach allows us to expose the tumor cells to single drugs under carefully controlled conditions, even if this would be an inappropriate drug for that particular patient. We are then able to look concomitantly at cytotoxicity, and molecular markers of resistance in the same experiment.
Anthracyclines have a mechanism of action that includes TOPO IIα inhibition via DNA intercalation. Resistance to anthracyclines is thought to be mediated by a number of different mechanisms, which include mutation or alteration of its target enzyme, TOPO IIα, and up-regulation of drug efflux proteins, such as BCRP, MRP1, MVP and MDR-1 [25] . Our data show that many of the cell line data are correct: in most solid tumors, it appears that anthracycline and topotecan exposure do lead to decreased topoisomerase II and I expression respectively, while inducing the expression of drug efflux pump molecules. The reason for the alteration in topoisomerase II expression following topotecan exposure is not clear, but topotecan does affect cell proliferation, and any reduction in proliferation would indirectly affect the expression of topoisomerase II alpha induced during S phase. However, our results also suggest that the heterogeneity of chemosensitivity between tumors is reflected by heterogeneity of molecular determinants of resistance/sensitivity.
The increased TS levels in ECF and 5-FU exposed cells is consistent with a number of previous reports. Gene amplification of TS with consequent increases in TS mRNA and protein has been observed in cell lines that are resistant to 5-FU and fluorodeoxyuridine (FUDR) [26, 27] . Treatment with 5-FU has been shown to acutely induce TS expression in cell lines, animal models and human tumors [19, [28] [29] [30] . In general there is strong evidence that the expression of DPD and TS in GI cancers is predictive of response to 5-FU. It should be noted that the concomitant measurement of both these markers markedly enhanced the ability to predict tumor response to 5-FUbased chemotherapy in a number of studies [31] [32] [33] [34] .
Gene profiling and drug response
There are few studies comparing gene expression before and after chemotherapy. A few studies have reported microarray data in biopsy material taken before and after (or even during) chemotherapy. These studies are of great interest, though normal cell effects cannot be excluded from the results. Buchholz et al. [35] employed cDNA microarray to measure gene expression changes during chemotherapy in 5 patients with breast cancer. Clarke et al. [36] studied gene expression changes in 18 rectal cancer patients undergoing therapy with Mitomycin C or 5-FU. This study reported a number of genes implicated in protein synthesis and RNA metabolism to be significantly decreased during drug treatment. These studies are not directly comparable: tumors of different types respond better to different drugs, and differences in their adaptation to these drugs are therefore expected on the basis of their innate sensitivity or resistance.
The potential for positive selection: molecular chess
It is common to show a cross-over effect with clinical trials of treatments with differing mechanisms of action, in which patients treated with one type of chemotherapy show sensitivity to the alternative regimen following fail-ure of the one to which they were allocated. The recognition that selection of a molecular phenotype by exposure to one anti-cancer agent may leads to the expression of molecular targets for other drugs raises the possibility that it might be possible to enhance sensitivity to second-line or maintenance therapy by careful selection of patients for first-line therapy [37] . This approach would provide patients with a "backstop" for their first-line chemotherapy. One can envisage a series of interlocking treatments using drugs with specific molecular targets, monitored by molecular assays, which would allow the oncologist to employ a form of molecular chess to defeat the tumor. This approach might overcome the inherent heterogeneity, which is likely to underlie the variable results obtained from sequential chemotherapy to date. Assessment of this process in tumors could provide predictive assays allowing the oncologist to tailor therapy to the patient and avoid the development of resistance within the tumor.
